EichorEICHOR
Condition: Esophagogastric Junction Disorder Synced from ClinicalTrials.gov · August 09, 2026

Recruiting studies: Esophagogastric Junction Disorder

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric
Phase 1/Phase 2 · 1 location(s) · Henan Cancer Hospital · NCT07334431Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer
Phase 3 · 5 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT04821778A Prospective Study on Esophagogastrostomy by an Innovative Surgical Technique
NA · 1 location(s) · Huashan Hospital · NCT06300879A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Phase 1 · 30 location(s) · Pfizer · NCT07090499Docetaxel, Oxaliplatin and 5-FU for Gastric Cancer With Inoperable Malignant Bowel Obstruction
Phase 2 · 1 location(s) · Sixth Affiliated Hospital, Sun Yat-sen University · NCT04840264Spanish Registry of Esophagogastric Cancer
Phase N/A · 38 location(s) · Fundación Sociedad Española de Oncologia Médica · NCT04958720A Study of KK2269 in Adult Participants With Solid Tumors
Phase 1 · 11 location(s) · Kyowa Kirin Co., Ltd. · NCT06266299Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenoca
Phase 2 · 2 location(s) · Jiangsu HengRui Medicine Co., Ltd. · NCT07102901First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
Phase 1 · 10 location(s) · Plexium, Inc. · NCT07284186A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced
Phase 1/Phase 2 · 16 location(s) · BioNTech SE · NCT07186842Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
Phase 1/Phase 2 · 25 location(s) · AstraZeneca · NCT06005493Pembrolizumab, Olaparib, Recurrent/Advanced Gastric and Gastro-esophageal Junction(GEJ) Cancer
Phase 1/Phase 2 · 1 location(s) · Yonsei University · NCT04592211A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic So
Phase 1/Phase 2 · 120 location(s) · Daiichi Sankyo · NCT06330064A Multicenter Cancer Biospecimen Collection Study
Phase N/A · 1 location(s) · Cofactor Genomics, Inc. · NCT04510129A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
Phase 1 · 48 location(s) · Seagen, a wholly owned subsidiary of Pfizer · NCT06131840A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction Adenocarcinoma
Phase 2 · 1 location(s) · The First Affiliated Hospital of Xiamen University · NCT06415669IKS014 in Advanced Solid Tumors That Express HER2
Phase 1 · 13 location(s) · Iksuda Therapeutics Ltd. · NCT05872295Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesop
Phase 3 · 250 location(s) · Daiichi Sankyo · NCT06731478A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alon
Phase 1/Phase 2 · 67 location(s) · BioNTech SE · NCT07070232Pan-tumor MRD Study
Phase N/A · 2 location(s) · Paradigm Health · NCT06605404Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients Wi
Phase 1 · 1 location(s) · National Cancer Institute (NCI) · NCT06364410Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative G
Phase 3 · 10 location(s) · Sun Yat-sen University · NCT05918094Safety Comparison of Total Laparoscopic Proximal Gastrectomy With or Without Preservation of the Celiac Branch of the Va
NA · 1 location(s) · Fujian Cancer Hospital · NCT07142122KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy
Phase 2/Phase 3 · 1 location(s) · Shanghai JMT-Bio Inc. · NCT05427383Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT04771520A Phase 2 Clinical Study of ABSK061 and ABSK043
Phase 2 · 21 location(s) · Abbisko Therapeutics Co, Ltd · NCT06632262MRI and CT Simulation in the Evaluation of Tumor Response and Target Volume Definition for Esophageal or Esophagogastric
NA · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT02988921AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
Phase 2 · 52 location(s) · AstraZeneca · NCT06219941A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT for Resectable
Phase 1 · 4 location(s) · Institut für Klinische Krebsforschung IKF GmbH at Krankenhau · NCT07059299Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Te
Phase 1/Phase 2 · 105 location(s) · Boehringer Ingelheim · NCT06324357
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.